Immunoglobulin A Nephropathy

Rate of kidney replacement therapy for end-stage kidney disease due to primary glomerular disease varies between European countries and was highest for immunoglobulin A nephropathy and focal segmental glomerulosclerosis, study data show.

Urinary plasminogen and the ratio of measured to expected plasminogen may be independently linked to the risk of progression to end-stage kidney disease, data show.

The FDA has granted a 7-year orphan drug exclusivity period for Tarpeyo, a medication for the treatment of primary immunoglobulin A nephropathy, according to a press release.

Novartis has agreed to buy SanReno Therapeutics, a clinical-stage company that specializes in the development of treatments for kidney diseases, according to a press release.